Capmatinib, also known by its brand name Tabrecta, is a targeted therapy drug designed to inhibit the activity of the MET tyrosine kinase receptor. This receptor is often implicated in various types of cancer, particularly non-small cell lung cancer (NSCLC). Capmatinib works by blocking the signals that stimulate the growth and survival of cancer cells.
